72
Participants
Start Date
April 16, 2021
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
CFI-400945
The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
Azacitidine
Azacitidine will be given at its labeled dose and schedule
New York Presbyterian Weill Cornell Medical Center, New York
Norton Cancer Institute - Saint Matthews, Louisville
The Ohio State University Comprehensive Cancer Center, Columbus
The University of Texas MD Anderson Cancer Centre, Houston
City of Hope, Duarte
University of California Davis Comprehensive Cancer Center, Sacramento
University of Alberta, Edmonton
Princess Margaret Cancer Center, Toronto
Queen Mary Hospital, Hong Kong
Treadwell Therapeutics, Inc
INDUSTRY